{"filings":[{"id":110243,"accession_number":"0001193125-26-133331","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.03","2.04","5.02","8.01"],"status":"ready","headline":"IO Biotech files Chapter 7 bankruptcy, ceases operations, all directors and employees terminated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Chapter 7 bankruptcy petition in Delaware on March 31, 2026; company ceases operations.","Chapter 7 trustee to liquidate assets; it is unlikely common stockholders will receive any payment.","All board members (Peter Hirth, Helen Collins, etc.) resigned; CEO Mai-Britt Zocca and CFO Amy Sullivan terminated.","Default triggered on €22.5 million EIB loan; EIB may demand immediate repayment but stay under bankruptcy.","Audit of 2025 financials not completed; company will not file 10-K or any periodic reports."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110242,"accession_number":"0001193125-26-051790","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"IO Biotech receives Nasdaq MVLS deficiency notice; 180 days to comply","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received Feb 12, 2026; MVLS below $50M for 30 consecutive business days.","Company has until August 11, 2026 to regain compliance.","Stock continues trading on Nasdaq Global Select Market during cure period.","If not cured, Nasdaq will issue delisting notice; company may appeal.","No assurance of regaining compliance with MVLS or other listing rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110241,"accession_number":"0001193125-26-031987","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["2.05","5.02","8.01","9.01"],"status":"ready","headline":"IO Biotech explores strategic alternatives, cuts workforce, CMO departs, hires Raymond James","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Retained Raymond James as exclusive financial advisor to assist in exploration of strategic alternatives.","Board approved restructuring plan; expects $2.4M-$2.6M in one-time charges in Q1 2026.","Chief Medical Officer Qasim Ahmad's employment will end effective Feb 15, 2026.","Company implementing significant global workforce reduction to reduce operating expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110240,"accession_number":"0001193125-26-017164","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IO Biotech to explore strategic alternatives including merger, sale, or liquidation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company to evaluate merger, business combination, sale of assets, or liquidation and dissolution.","Further reduction-in-force and cost-cutting measures are also under consideration.","No timetable for the process; no assurance any transaction will occur.","IO Biotech (Nasdaq: IOBT) is a clinical-stage cancer vaccine developer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126826,"accession_number":"0001193125-25-327089","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"IO Biotech receives Nasdaq bid price deficiency notice; has until June 16, 2026 to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified IO Biotech on Dec 17, 2025 that bid price < $1.00 for 30 consecutive days.","Company has 180 calendar days, until June 16, 2026, to regain compliance.","To comply, closing bid price must be >= $1.00 for at least 10 consecutive trading days.","If not compliant by June 2026, may apply for a second 180-day period by transferring to Nasdaq Capital Market.","No immediate effect on listing; stock continues trading on Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126825,"accession_number":"0001193125-25-291504","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IO Biotech chief accounting officer Burkavage resigns; CFO Sullivan to succeed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Burkavage resigns as SVP and Chief Accounting Officer effective December 12, 2025 to pursue another opportunity; no dispute with company.","CFO Amy Sullivan designated as principal accounting officer upon Burkavage's departure; no new compensatory arrangements entered.","Sullivan's biography previously disclosed in IO Biotech's April 2025 definitive proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126824,"accession_number":"0001193125-25-285282","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"IO Biotech updates investor deck for Jefferies conference; no specific new data in exhibit","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company will present at Jefferies Global Healthcare Conference on November 18, 2025.","Updated investor deck posted to company website on November 18, 2025, and filed with SEC.","Filing exhibit contains only a disclaimer and forward-looking statements; no new financial or operational metrics.","No changes to business strategy, pipeline, or guidance disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126823,"accession_number":"0001193125-25-281657","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IO Biotech Q3: Phase 3 melanoma trial narrowly misses PFS endpoint; cash $30.7M, runway to Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 IOB-013 trial in advanced melanoma showed PFS improvement but narrowly missed statistical significance; FDA meeting in December for new registrational trial design.","Q3 total operating expenses $19.4M, down from $26.5M YoY; R&D expenses $13.7M vs $20.2M prior year.","Cash and equivalents $30.7M as of Sep 30, 2025, down from $60.0M at Dec 31, 2024; expects to fund operations through Q1 2026.","Cash increased $2.5M in Q3 from €12.5M EIB loan drawdown and $6.6M net ATM proceeds.","Pre-clinical data for pipeline candidates IO112 (arginase 1) and IO170 (TGF-β) presented at SITC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143602,"accession_number":"0001193125-25-221704","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["2.05","7.01","8.01","9.01"],"status":"ready","headline":"FDA advises IO Biotech not to submit BLA for Cylembio; workforce cut by ~50%","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA recommends against BLA submission based on IOB-013 trial data (PFS improved but missed statistical significance).","Company plans new registrational study for first-line advanced melanoma; also engaging European regulators.","Restructuring reduces workforce ~50%; expects $1.0-1.5M severance charges in Q3 2025.","Cash runway extended into Q1 2026 to focus on regulatory path for Cylembio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143601,"accession_number":"0001193125-25-180830","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IO Biotech Q2 net loss $26.2M; Ph3 Cylembio trial misses PFS endpoint, plans FDA meeting fall 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 trial of Cylembio+Keytruda in advanced melanoma showed clinical improvement in PFS but narrowly missed statistical significance.","Company plans to meet with FDA in fall 2025 to discuss data and potential BLA submission for Cylembio.","Net loss of $26.2M for Q2 2025 vs $20.7M in Q2 2024; R&D expenses $16.7M, G&A $6.5M.","Cash and equivalents $28.1M at June 30, 2025; plus €12.5M EIB loan received July 4, funding into Q1 2026.","Upcoming investor conferences: Morgan Stanley (Sept 9) and H.C. Wainwright (Sept 10) with management presentations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143600,"accession_number":"0001193125-25-177471","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"IO Biotech Phase 3 Cylembio trial misses statistical significance; PFS improved 19.4 vs 11.0 mo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint PFS HR=0.77 (CI 0.58-1.00), p=0.056, missed significance threshold p≤0.045.","Median PFS 19.4 months (Cylembio+pembrolizumab) vs 11.0 months (pembrolizumab alone).","PD-L1 negative subgroup median PFS 16.6 vs 3.0 months (HR 0.54, nominal p=0.006).","OS trend HR=0.79 (CI 0.57-1.10); company expects OS maturity in 6-9 months.","Estimated cash $28.1M as of June 30, plus €12.5M drawn July 4; runway into Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161793,"accession_number":"0001193125-25-151511","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["3.02","8.01","1.01","9.01"],"status":"ready","headline":"IO Biotech draws €12.5M Tranche B from EIB, issues warrant for 4.22M shares at $1.3159","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Satisfied conditions to draw €12.5M second tranche (Tranche B) from EIB loan facility of up to €57.5M.","Issued Tranche B warrant to purchase up to 4,221,867 shares of common stock at strike price $1.3159 per share.","Drawdown is expected on or around July 4, 2025.","Warrant terms mirror those disclosed in the December 20, 2024 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161792,"accession_number":"0001193125-25-143658","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"IO Biotech enters CEO severance agreement providing 12-18 months pay and equity vesting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Severance pay: 12 months base salary on qualifying termination; 18 months if termination within 6 months pre- or 12 months post-Change in Control.","Equity awards: 12-month vesting acceleration (standard) or 100% vesting at target (Change in Control scenario).","Pro-rated bonus for termination year plus unpaid prior-year bonus; subject to release and non-compete compliance.","CEO Mai-Britt Zocca: addendum to existing service agreement effective June 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161791,"accession_number":"0001193125-25-137894","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"IO Biotech stockholders elect David Smith to board, ratify EY as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["David Smith elected as Class I director with 40,444,898 votes for, 3,010,542 withheld, 8,622,498 broker non-votes.","Ratification of EY Godkendt Revisionspartnerselskab as independent auditor: 51,581,966 for, 183,927 against, 312,045 abstain.","Annual Meeting held June 5, 2025; both proposals approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161790,"accession_number":"0001193125-25-134502","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IO Biotech regains Nasdaq minimum bid price compliance after deficiency notice","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received December 26, 2024 notice from Nasdaq for bid price below $1.00 for 30 consecutive days.","On June 3, 2025, Nasdaq Staff confirmed closing bid price at $1.00+ for 10 consecutive business days.","Company has regained compliance with Nasdaq Listing Rule 5450(a)(1); matter is closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161789,"accession_number":"0001193125-25-119406","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IO Biotech Q1 net loss $22.4M; Phase 3 melanoma vaccine readout on track for Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.4M in Q1 2025 vs $19.5M in Q1 2024; R&D expenses rose to $16.4M.","Cash and equivalents $37.1M at March 31, 2025, down from $60.0M at Dec 31, 2024; Q1 cash burn $22.9M.","Drew €10.0M tranche A of EIB loan on May 6; believes conditions met for €12.5M second tranche.","Phase 3 trial primary endpoint (PFS) readout on track for Q3 2025; BLA submission planned in 2025.","Enrollment completed in Phase 2 basket trial (IOB-032) for SCCHN/melanoma; initial data expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161788,"accession_number":"0001193125-25-107501","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["3.02","8.01","1.01","9.01"],"status":"ready","headline":"IO Biotech issues warrant to EIB for up to 5.6M shares at $0.8891; €10M draw expected May 6","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued Tranche A Warrant to EIB to purchase up to 5,623,664 shares of common stock at $0.8891 per share.","Warrant issued in connection with €10M draw under previously announced EIB loan facility of up to €57.5M.","Drawdown of €10M Tranche A loan expected on or around May 6, 2025.","Warrant issued in private placement exempt from registration under Section 4(a)(2) of Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179885,"accession_number":"0001193125-25-045673","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"IO Biotech expects Phase 3 PFS readout in Q3 2025; cash of $60M extends runway to Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 trial (advanced melanoma) PFS primary endpoint readout delayed to Q3 2025; BLA submission still planned by year-end 2025.","Cash and equivalents ~$60M as of Dec 31, 2024; secured up to €57.5M EIB debt, extending runway into Q2 2026.","Phase 2 basket trial (resectable melanoma/SCCHN) enrollment completed at 95 patients; initial data expected H2 2025.","Phase 2 IOB-022 met primary endpoint ORR in SCCHN; promising PFS in SCCHN and NSCLC; longer-term data H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196676,"accession_number":"0001193125-24-285936","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2024-12-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"IO Biotech receives Nasdaq bid price deficiency notice; stock at risk of delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on Dec 26, 2024: common stock bid price below $1.00 for 30 consecutive days.","Company has 180 days, until June 24, 2025, to regain compliance by closing at $1.00+ for 10 consecutive days.","Failure to comply could lead to delisting; may qualify for additional 180-day period if transferred to Nasdaq Capital Market.","No immediate effect on listing; trading continues on Nasdaq Global Select Market pending compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196675,"accession_number":"0001193125-24-282502","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"IO Biotech secures up to €57.5M EIB debt facility; extends cash runway into Q2 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Total committed tranches of €37.5M (Tranche A €10M, B €12.5M, C €15M) plus €20M uncommitted accordion.","First two tranches expected for disbursement in Q1 2025; each tranche matures in 6 years at 8% fixed interest.","Tranche C requires $50M cash raise and US or EU marketing authorization submission for IO102-IO103 within 36 months.","Warrants to be issued to EIB upon each tranche disbursement; loan is unsecured with no minimum cash covenants.","Cash runway now expected into Q2 2026, funding ongoing clinical trials and pre-commercialization activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196674,"accession_number":"0001193125-24-278985","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"IO Biotech adopts amended and restated bylaws effective December 13, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended bylaws revise procedural mechanics for stockholder director nominations and other business proposals.","New provisions address compliance with Rule 14a-19 under the Exchange Act regarding universal proxy.","Updates to stockholder meeting procedures and director eligibility requirements are included.","Changes conform to recent amendments to the Delaware General Corporation Law.","Other ministerial and clarifying amendments were made effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196673,"accession_number":"0001193125-24-255127","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IO Biotech Q3 net loss $24.0M; Phase 3 melanoma trial on track for PFS in H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.0M for Q3 2024 vs $21.7M in Q3 2023; R&D expenses $20.2M up from $17.7M.","Cash $80.2M as of Sep 30, 2024, down from $143.2M; cash runway into Q4 2025.","Phase 3 trial IO102-IO103 + pembrolizumab in advanced melanoma: PFS primary endpoint expected H1 2025.","Phase 2 SCCHN cohort met primary endpoint; data presented at ESMO and SITC.","Plans BLA submission in 2025 and potential US launch in 2026; IND for IO112 in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212975,"accession_number":"0001193125-24-211080","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"IO Biotech Phase 3 trial IDMC recommends continuation; PFS endpoint expected H1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IDMC recommends Phase 3 trial of IO102-IO103 + pembrolizumab continue without modifications after interim analysis.","Interim ORR analysis did not meet pre-specified high statistical bar (p≤0.005); most alpha preserved for PFS.","Primary endpoint PFS event-driven at 226 events; trial 89% powered to detect 35% risk reduction; projected H1 2025.","No new safety signals observed; 407 patients enrolled across 100+ centers in US, EU, Australia, and elsewhere.","Phase 2 basket trial data for NSCLC and SCCHN accepted for presentations at ESMO and other fall meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212974,"accession_number":"0001193125-24-199383","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IO Biotech Q2 net loss $20.7M; cash runway into Q4 2025; Phase 3 interim analysis expected Q3 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $20.7M for Q2 2024 vs $21.2M in Q2 2023; R&D expenses $15.8M.","Cash and equivalents $100.7M at June 30, 2024, down from $143.2M at year-end 2023.","Phase 3 trial (IOB-013) interim analysis for ORR expected Q3 2024; primary PFS endpoint in H1 2025.","Potential BLA submission in Q4 2024 if interim analysis supports accelerated approval.","Completed enrollment in Phase 2 basket trial (IOB-022) for NSCLC and SCCHN; data to be presented at ESMO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232061,"accession_number":"0001193125-24-159193","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"IO Biotech stockholders elect three directors and ratify EY as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kathleen Sereda Glaub, Peter Hirth, and Mai-Britt Zocca elected as Class III directors until 2027.","Votes for each director exceeded 42 million; broker non-votes 3.9 million on each.","Ratification of EY as independent auditor for FY 2024 approved with 47.2 million for, 67k against.","No other matters were voted on at the June 6, 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232060,"accession_number":"0001193125-24-137754","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IO Biotech Q1 2024 net loss $19.5M; Phase 3 melanoma interim ORR data expected Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.5M for Q1 2024 vs $17.0M in Q1 2023; R&D expenses $14.3M (up from $11.9M).","Cash and cash equivalents $118.0M at March 31, 2024; cash runway expected into Q4 2025.","Phase 3 trial (IOB-013) of IO102-IO103 in advanced melanoma: interim ORR analysis expected Q3 2024; PFS analysis projected H1 2025.","Completed Phase 2 basket trial (IOB-022) enrollment; Phase 2 basket trial (IOB-032) expanded with randomized melanoma cohort.","Appointed Faiçal Miyara as Chief Business Officer and Marjan Shamsaei as SVP Commercial & Portfolio Lead."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232059,"accession_number":"0001193125-24-118498","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IO Biotech director Jack Nielsen resigns for health reasons effective April 24","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jack Nielsen resigned from the Board of Directors on April 24, 2024.","Resignation due to health reasons, not any disagreement with the Company or Board.","No replacement named; Board size reduced accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250340,"accession_number":"0001193125-24-059364","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IO Biotech Q4 net loss $26.2M; Phase 3 melanoma trial enrollment complete, interim ORR analysis expected Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $26.2M in Q4 2023 vs $20.1M YoY; R&D expenses $21.8M on Phase 3 trial costs.","Cash $143.2M at Dec 31, 2023; operational runway projected into Q4 2025.","Completed enrollment of 380 patients in pivotal Phase 3 trial of IO102-IO103 + Keytruda in advanced melanoma.","Planned interim ORR analysis from first 225 patients expected in Q3 2024; PFS primary endpoint anticipated H2 2025.","First patient dosed in Phase 2 basket trial of IO102-IO103 neoadjuvant/adjuvant in resectable solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250339,"accession_number":"0001193125-24-003947","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"IO Biotech presents at J.P. Morgan conference; confirms cash runway into Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Company presenting at 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024.","Updated corporate presentation posted; confirms projected cash runway through Q4 2025.","No new clinical data or financial results disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267897,"accession_number":"0001193125-23-275395","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"IO Biotech Q3 net loss $21.7M, cash $165.5M; Phase 3 melanoma trial fully enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.7M in Q3 2023 vs $15.7M Q3 2022; R&D expenses $17.7M (up from $10.0M) driven by Phase 3 trial.","Cash and equivalents $165.5M at Sept 30, 2023, including $75M private placement; cash runway into Q4 2025.","Completed enrollment of 380 patients in pivotal Phase 3 (IO102-IO103 + pembrolizumab) for advanced melanoma; interim ORR expected Q3 2024, PFS H2 2025.","Appointed Helen Collins, MD to board; she serves as Chair of R&D Committee and brings extensive oncology drug development experience.","Presented encouraging preliminary Phase 2 data at WCLC and ESMO; three non-clinical posters at SITC 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285124,"accession_number":"0001193125-23-209874","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"IO Biotech Q2 net loss $21.2M; Phase 3 melanoma trial reaches 225-patient milestone; $75M private placement closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.2M (vs $18.5M Q2 2022); R&D spend $16.5M on Phase 3 trial execution.","Cash and equivalents $110.1M; expected to fund operations into Q4 2025.","Phase 3 IOB-013/KN-D18 enrolled 225 patients; target raised to 380, full enrollment by end 2023.","Interim ORR analysis one year post 225 randomized may support US accelerated BLA submission.","Appointed Heidi Hunter to Board; Priyanka Belawat resigned; closed $75M private placement (37M shares+warrants)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285123,"accession_number":"0001193125-23-204538","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"IO Biotech raises ~$75M in private placement; cash runway extended to Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$75.1M from sale of 37.1M shares and warrants at $2.025 combined price.","Warrants to purchase 37.1M shares at $2.47, exercisable for 42 months from issuance.","Institutional investors include Lundbeckfonden BioCapital, Novo Holdings, Vivo Capital, and others.","Joint placement agents are Morgan Stanley and Piper Sandler, earning ~6% fee.","Management expects cash to fund operations into Q4 2025, supporting pivotal Phase 3 and Phase 2 trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285122,"accession_number":"0001193125-23-188851","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2023-07-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"IO Biotech appoints Qasim Ahmad as CMO, promotes Eric Faulkner to CTO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Qasim Ahmad, MD, appointed CMO effective July 15; previously Novartis SVP, US Head Clinical Development & Medical Affairs.","Eva Ehrnrooth transitions from CMO to Senior Clinical Advisor; departure not due to any disagreement.","Eric Faulkner promoted to CTO; previously Sr. VP CMC, will oversee CMC and Quality for commercial readiness.","Ahmad granted inducement option for 288,153 shares vesting over 4 years (25% cliff at year one).","Changes position company for BLA filing and next stage of growth; Ahmad based in US."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304969,"accession_number":"0001193125-23-166540","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"IO Biotech hits 225-patient enrollment milestone in Phase 3 melanoma trial; expanded to 380","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["225 patients randomized in Phase 3 trial of IO102-IO103 + pembrolizumab for advanced melanoma.","Interim ORR analysis now triggered; positive data could enable BLA for accelerated approval in U.S.","Trial enrollment increased to 380 patients to potentially accelerate primary PFS endpoint.","Company expects full enrollment by year-end 2023; cash runway through Q3 2024.","CEO notes potential first vaccine approval in 2025 if interim analysis is positive."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304968,"accession_number":"0001193125-23-164443","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"IO Biotech shareholders elect directors and approve officer exculpation amendment at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Priyanka Belawat and Christian Elling elected as Class II directors until 2026 annual meeting.","Amendment to Certificate of Incorporation to provide officer exculpation approved: 20,021,960 for, 115,161 against.","Ratification of EY Godkendt Revisionspartnerselskab as independent auditor for FY2023 approved: 20,815,596 for, 111,302 against.","Broker non-votes were 789,675 on director elections and the exculpation proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304967,"accession_number":"0001193125-23-142000","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IO Biotech reports Q1 net loss of $17.0M; Phase 3 melanoma trial on track for mid-2023 enrollment milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.0M for Q1 2023, nearly flat vs $17.2M in Q1 2022.","Cash and equivalents $128.5M as of March 31, 2023; expected to fund operations through Q3 2024.","Phase 3 pivotal trial (IOB-013) in advanced melanoma: expects 225 patients randomized by mid-2023, full enrollment by end of 2023.","Phase 2 basket trial (IOB-022) in lung cancer: 4 partial responses, 4 stable disease among 9 evaluable patients; safety consistent.","FDA cleared IND for IO102-IO103 in neo-adjuvant/adjuvant solid tumors; Phase 2 trial to start H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304966,"accession_number":"0001193125-23-108320","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2023-04-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IO Biotech board member Vanessa Malier resigns effective April 17, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vanessa Malier resigned from the Board on April 17, 2023.","Resignation not due to any disagreement with the Company or Board.","No replacement director announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324460,"accession_number":"0001193125-23-070166","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2023-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IO Biotech reports 2022 net loss of $71.5M; cash runway through Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $71.5M for 2022 vs $67.9M for 2021; Q4 net loss $20.1M vs $21.3M.","R&D expenses $47.0M (+56% YoY) driven by Phase 3 trial execution; G&A $24.4M (+120%).","Cash and equivalents $142.6M at Dec 31, 2022, down from $211.5M; expects runway through Q3 2024.","Phase 3 advanced melanoma trial (IOB-013) targets 75% enrollment by mid-2023; interim ORR analysis could enable accelerated BLA.","Appointed Amy Sullivan CFO (Oct 2022) and Devin Smith GC (Jan 2023)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324459,"accession_number":"0001193125-23-069559","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2023-03-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"IO Biotech reports ~$142M cash as of Dec 31, 2022; runway through Q3 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash and cash equivalents of ~$142M as of Dec 31, 2022 (subject to audit).","Cash runway projected through Q3 2024, per updated corporate presentation.","Updated presentation to be used at Oppenheimer 33rd Annual Healthcare Conference on Mar 14, 2023.","No other financial results or guidance changes disclosed; preliminary cash is unaudited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324458,"accession_number":"0001193125-23-067793","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"IO Biotech discloses ~1% of cash held at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approximately 1% of total cash and cash equivalents held at Silicon Valley Bank in operating accounts.","Remaining 99% of cash held at other institutions; exposure is limited.","Disclosure filed March 10, 2023, amid SVB liquidity crisis affecting broader market.","Company continues to support U.S. operations through the affected accounts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324457,"accession_number":"0001193125-23-040254","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2023-02-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IO Biotech launches $19.5M ATM equity program with Cowen, up to $75M total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement for at-the-market offering of common stock up to $19.5 million.","Sales agreement with Cowen and Company allows additional sales up to $75 million aggregate.","Proceeds to fund preclinical studies, clinical trials, product acquisitions, and working capital.","Cowen receives 3% commission on gross sales; shares sold through Nasdaq or other markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324456,"accession_number":"0001193125-23-004173","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"IO Biotech: Phase 3 melanoma trial continues; Phase 2 lung cancer shows 4 partial responses; $142.7M cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IDMC recommends Phase 3 melanoma trial continue without changes; enrolling at >80 sites globally.","Initial Phase 2 basket data: 9 evaluable NSCLC patients: 4 partial responses, 4 stable disease, 1 progressive disease.","New investigator-initiated study with Johns Hopkins for SCCHN expected H1 2023; total 4 IITs ongoing.","Preliminary cash $142.7M at Dec 31, 2022; expected to fund operations into mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342336,"accession_number":"0001193125-22-281199","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IO Biotech reports Q3 net loss $15.7M; Phase 3 melanoma trial site activation accelerates; cash $151.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.7M (vs $4.5M in Q3 2021); R&D expenses $10.0M (up from $4.1M) driven by Phase 3 trial costs.","Cash $151.2M as of Sep 30, 2022 (down from $211.5M at Dec 31, 2021); expected to fund operations into mid-2024.","Phase 3 trial site activation accelerated: 55 sites actively enrolling (up from 19 at end of July 2022).","Updated Phase 1/2 data: median OS 46.8 mo, median PFS 22.5 mo, complete response rate 50% in PD-1 naive patients.","Named Amy Sullivan as CFO in October 2022; new clinical collaboration with Merck for neoadjuvant/adjuvant trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342335,"accession_number":"0001193125-22-262152","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2022-10-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"IO Biotech appoints Amy Sullivan as CFO effective Oct 15, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amy Sullivan, 53, appointed CFO and Principal Financial Officer, effective October 15, 2022.","Annual base salary of $425,000 and target bonus of 45% of base salary.","Granted option for 288,152 shares; vests 25% at 1 year, then monthly over 3 years.","Ms. Sullivan previously served as CFO at TABA and chief strategy officer at Kiadis Pharma, leading its sale to Sanofi.","She brings 25+ years of life sciences finance and corporate strategy experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359072,"accession_number":"0001193125-22-218611","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IO Biotech reports Q2 net loss of $18.5M; cash $170.1M to fund data readouts into mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.5M for Q2 2022 vs $38.4M in Q2 2021, driven by higher R&D and G&A costs.","R&D expenses $12.2M (up from $6.7M) due to Phase 3 trial initiation and increased headcount.","Cash and equivalents $170.1M at June 30, 2022, down from $211.5M at Dec 31, 2021.","Initiated Phase 3 IOB-013/KN-D18 trial of IO102-IO103 + pembrolizumab in advanced melanoma.","Phase 2 basket trial (IOB-022/KN-D38) dosing started; preliminary data expected H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377886,"accession_number":"0001193125-22-160961","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2022-05-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"IO Biotech stockholders elect Nielsen and Smith as Class I directors, ratify EY as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jack B. Nielsen elected with 22,460,202 for, 938,718 withheld, 320,057 broker non-votes.","David V. Smith elected with 23,387,185 for, 11,735 withheld, 320,057 broker non-votes.","Ratification of EY as independent auditor for FY2022: 23,707,581 for, 10,261 against, 1,136 abstain, no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377885,"accession_number":"0001193125-22-151812","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IO Biotech Q1 2022 net loss $17.2M; cash $187.9M; Phase 2 trial initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.2M for Q1 2022 vs $3.7M in Q1 2021; R&D expenses $10.3M (up $7.5M).","Cash and equivalents $187.9M at March 31, 2022, down from $211.5M at Dec 31, 2021; runway to mid-2024.","Initiated Phase 2 trial (IOB-022/KN-D38) of IO102-IO103 with pembrolizumab in first-line treatment.","Updated Phase 1/2 data for IO102-IO103 + nivolumab in metastatic melanoma showed 73% 3-year survival probability.","Phase 3 trial (IOB-013/KN-D18) with Merck ongoing; guidance on interim readout timing expected mid-2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377884,"accession_number":"0001193125-22-150146","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2022-05-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Keith Vendola departs; Brian Burkavage appointed Chief Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Keith Vendola terminated as CFO by mutual agreement effective May 9, 2022; no disagreement with company or board.","CEO Mai-Britt Zocca will serve as Principal Financial Officer until CAO appointment.","Brian Burkavage, previously VP of Finance, appointed Chief Accounting Officer effective May 12, 2022.","Burkavage was Controller at Passage BIO (2020-2021) and Director of FP&A at Aclaris Therapeutics (2017-2020)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377883,"accession_number":"0001193125-22-105541","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2022-04-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two IO Biotech directors to step down at 2022 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Claus Andersson and Dr. Emmanuelle Coutanceau notified the Board they will not stand for reelection.","Effective at the Company's 2022 annual meeting of stockholders.","Decisions are not due to any disagreement with the Company or Board regarding operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396197,"accession_number":"0001193125-22-091856","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2022-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IO Biotech reports FY2021 net loss of $67.9M; cash of $211.5M supports operations into mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $67.9M in FY2021 vs $12.0M in FY2020; R&D expenses rose to $30.2M from $8.5M.","Cash and cash equivalents of $211.5M at Dec 31, 2021; expected runway through multiple data readouts into mid-2024.","Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 + KEYTRUDA in advanced melanoma began patient recruitment.","Updated Phase 1/2 data (MM1636) in metastatic melanoma to be presented at AACR 2022.","Management notes longer-than-expected lead times in clinical site activation and patient enrollment."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151092.5294117647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-31T23:59:59+00:00|396197"}